Talk to a Viviscal Hair Care Advisor: AU 1800 222 099 - NZ 0800 380 218

ViviscalViviscal

25 years of research
The Clinical Trials Process
RESEARCHER

40 females

72 females

15 females

Glynis Ablon, M.D., FAAD, Ablon Skin Institute Research Center, University of California, Los Angeles, California, U.S.A.; and Steven Dayan, M.D., FACS, DeNova Research, Chicago, Illinois, U.S.A.
Thomas J. Stephens & Associates, Inc., Dallas Research Center, Carrollton, Texas, U.S.A.
Glynis Ablon, M.D., FAAD, Ablon Skin Institute Research Center, University of California, Los Angeles, California, U.S.A.
RESULTS

6-month, multi-center, randomized, double-blind, placebo-controlled clinical trial

Hypothesis: ingestion of oral Viviscal supplement will strengthen and promote terminal hairs in female subjects, ages 21-75, who have self-perceived thinning hair

Estimated publication date: summer 2014

6-month double-blind, placebo-controlled clinical trial demonstrated statistically significant results:

  • 18.3% reduction in hair shedding vs. placebo
  • 7.4% increase in hair thickness vs. placebo

Abstract presented: 7th World Congress for Hair Research (2013; Edinburgh, Scotland)

6-month double-blind, placebo-controlled clinical trial demonstrated statistically significant results:

  • 125% increase in terminal hairs vs. placebo group
  • 
  • Significant, self-perceived improvements in overall  hair volume, thickness and scalp coverage
  • 
  • Published: The Journal of Clinical and Aesthetic Dermatology (Nov. 2012)
 

  1. Thomas J. Stephens & Associates, Inc.
  2. Glynis Ablon, M.D., F.A.A.D., Ablon Skin Institute Reasearch Center, University of California, Los Angeles
  3. Brook Jackson, M.D., Skin Wellness Center of Chicago
  4. Thomas J. Stephens & Associates, Inc.
  5. José Marcos Pereira, M.D., Brazil